Drug Profile
Research programme: fibroblast growth factor receptor antagonists - Celon Pharma
Latest Information Update: 28 Jul 2021
Price :
$50
*
At a glance
- Originator Celon Pharma
- Class Antineoplastics; Small molecules
- Mechanism of Action Fibroblast growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Jul 2021 No recent reports of development identified for preclinical development in Solid-tumours in Poland